2017 – 2025 Global Industry Analysis on Antithrombotic/Anticoagulant Drugs Industrial Trend and Market Demand - Size, Share, Growth, Trends and Forecast
"Antithrombotic/Anticoagulant
Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends
and Forecast 2017 - 2025"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
.
.
Description-
'
'
Antithrombotic
is a drug that helps prevent the formation of thrombus or clot.
Antithrombotic and anticoagulant agents are drugs used to reduce the
formation of blood clots by reducing the body’s capability to form
a blood clot. These drugs act by preventing the production of vitamin
K in the liver. Antiplatelet, anticoagulant, and thrombolytic agents
are different types of antithrombotic agents that act through
different clotting processes. Arterial and venous thrombosis, the two
types of thrombosis, can be treated with antithrombotic drugs.
Get
Sample
Report
@
https://www.researchmoz.us/enquiry.php?type=S&repid=170654
'
'
The
three key causes of thrombosis are hypercoagulability, abnormal flow
of blood, and injury caused to endothelial cells of the blood vessel
wall. These causes result from genetic conditions, inactivity,
smoking, blood vessel damage, pregnancy, and obesity. Currently,
thrombosis and associated disorders including myocardial infarction,
stroke, and pulmonary embolism are primarily treated with off-patent
anticoagulant drugs viz. warfarin and heparin. The other form of
antithrombotic drugs i.e. aspirin is also off-patent. With a few
patented effective cures available in the market, pharmaceutical
companies have ample opportunities to innovate new products. The new
drugs could be profitable for them, as the burgeoning world
population would ensure steady increase in the demand for such
life-saving drugs. The global antithrombotic/anticoagulant drugs
market is expected to witness high growth during the forecast period,
owing to factors such as high availability of these drugs and chronic
conditions associated with thrombosis that require long-term drug
administration.
The antithrombotic/anticoagulant drugs market has
been segmented by drug class, application, route of administration,
and end-user. Based on drug class, the global
antithrombotic/anticoagulant drugs market has been segmented into
coumarins & indandiones, factor Xa inhibitors, heparins, and
thrombin inhibitors. Based on application, the market can be
segmented into atrial fibrillation, deep vein thrombosis, artificial
heart valve, pulmonary embolism, prevention of blood clots (for
example, genetic clotting disorders, stroke, and trauma), and heart
attack. All over the world, more than 10 million deaths are caused by
arterial thrombotic events every year. Rising prevalence of
cardiovascular diseases and accidental injuries is a key factor
expected to boost the antithrombotic/anticoagulant market during the
forecast period.
Based on route of administration, the global
antithrombotic/anticoagulant drugs market has been segmented into
oral route and parenteral route. The parenteral route segment is
expected to witness high growth during the forecast period, owing to
rapid onset of action shown by parenteral drugs. By end-user, the
market has been segmented into hospitals, specialty clinics, and
ambulatory surgical centers. Among these, the hospitals segment
accounted for a major market share in 2016, while the specialty
clinics segment is expected to witness high growth during the
forecast period. The global market for antithrombotic/anticoagulant
drugs is also driven by some other factors such as lack of specific
substitutes for antithrombotic and anticoagulant drugs, rising
geriatric population, rising prevalence of thrombosis, and recent
developments in the pharmaceutical industry.
Geographically, the global
antithrombotic/anticoagulant drugs market has been segmented into
North America, Latin America, Europe, Asia Pacific, and Middle East &
Africa. North America is expected to hold a high share of the global
antithrombotic/anticoagulant drugs market during the forecast period,
owing to development of new drugs and increasing prevalence of
cardiovascular and blood-related diseases in the region. The market
in Asia Pacific is expected to register high CAGR during the forecast
period owing to presence of high population based countries such as
India and China in the region. Both producers and sellers of
antithrombotic and anticoagulant drugs will see growth in the region.
Most of the times, these drugs are readily available in the market.
However, not a single drug is sufficiently effective in tackling the
disease and is without any side-effects. As a result, search for
newer and better versions of antithrombotic and anticoagulant drugs
without side-effects is being carried out by different players.
Key players operating in the global
antithrombotic/anticoagulant drugs market are Bayer AG, Novartis AG,
GlaxoSmithKline plc, Bristol Myers Squibb Company, Sanofi, Boehringer
Ingelheim GmbH, Genentech, Inc., AstraZeneca plc, Eli Lilly &
Company, and Pfizer, Inc.
The report offers a comprehensive evaluation of
the market. It does so via in-depth qualitative insights, historical
data, and verifiable projections about market size. The projections
featured in the report have been derived using proven research
methodologies and assumptions. By doing so, the research report
serves as a repository of analysis and information for every facet of
the market, including but not limited to: Regional markets,
technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive
primary research (through interviews, surveys, and observations of
seasoned analysts) and secondary research (which entails reputable
paid sources, trade journals, and industry body databases). The
report also features a complete qualitative and quantitative
assessment by analyzing data gathered from industry analysts and
market participants across key points in the industry’s value
chain.
A separate analysis of prevailing trends in the
parent market, macro- and micro-economic indicators, and regulations
and mandates is included under the purview of the study. By doing so,
the report projects the attractiveness of each major segment over the
forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
.
.
More
Clear Details get Table of Contents @
https://www.researchmoz.us/antithromboticanticoagulant-drugs-market-global-industry-analysis-size-share-growth-trends-and-forecast-2012-2018-report.html#table-of-content
Comments
Post a Comment